These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20846190)

  • 1. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome L
    Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190
    [No Abstract]   [Full Text] [Related]  

  • 2. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 3. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Apovian CM
    Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
    Fujioka K; Plodkowski R; O'Neil PM; Gilder K; Walsh B; Greenway FL
    Int J Obes (Lond); 2016 Sep; 40(9):1369-75. PubMed ID: 27328752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACS chemical neuroscience molecule spotlight on contrave.
    Mercer SL
    ACS Chem Neurosci; 2011 Sep; 2(9):484-6. PubMed ID: 22860172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
    Yanovski SZ; Yanovski JA
    JAMA; 2015 Mar 24-31; 313(12):1213-4. PubMed ID: 25803343
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
    Kolotkin RL; Chen S; Klassen P; Gilder K; Greenway FL
    Clin Obes; 2015 Oct; 5(5):237-44. PubMed ID: 26222044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
    Drugs R D; 2010; 10(1):25-32. PubMed ID: 20509712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
    Hong K; Herrmann K; Dybala C; Halseth AE; Lam H; Foreyt JP
    Clin Obes; 2016 Oct; 6(5):305-12. PubMed ID: 27477337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA
    R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone/bupropion for obesity.
    Drug Ther Bull; 2017 Nov; 55(11):126-129. PubMed ID: 29117992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
    Makowski CT; Gwinn KM; Hurren KM
    Obes Facts; 2011; 4(6):489-94. PubMed ID: 22249001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.